The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Open accessAbstract
Hepatocellular carcinoma (HCC) is a common cancer worldwide that primarily develops in cirrhosis resulting from chronic infection by hepatitis B virus and hepatitis C virus, alcoholic injury, and to a lesser extent from genetically determined disorders such as hemochromatosis. HCC has recently been linked to non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity and related metabolic disorders such as diabetes. This association is alarming due to the globally high prevalence of these conditions and may contribute to the rising incidence of HCC witnessed in many industrialized countries. There is also evidence that NAFLD acts synergistically with other risk factors of HCC such as chronic hepatitis C and alcoholic liver injury. Moreover, HCC may complicate non-cirrhotic NAFLD with mild or absent fibrosis, greatly expanding the population potentially at higher risk. Major systemic and liver-specific molecular mechanisms involved include insulin resistance and hyperinsulinemia, increased TNF signaling pathways, and alterations in cellular lipid metabolism. These provide new targets for prevention, early recognition, and effective treatment of HCC associated with NAFLD. Indeed, both metformin and PPAR gamma agonists have been associated with lower risk and improved prognosis of HCC. This review summarizes current evidence as it pertains to the epidemiology, pathogenesis, and prevention of NAFLD-associated HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 2×
“Obesity is characterized by a low-grade, chronic inflammatory response implicated in increased cancer risk in general [63,64].”
BackgroundManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“Several large-scale epidemiological studies have associated the increasingly prevalent overweight and obesity with a higher risk of HCC [7,8].”
BackgroundHepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Cancer cells often exhibit increased rates of fatty acid synthesis and accumulation of lipid droplets [77,78], suggesting that increased availability of lipids in hepatocytes may provide bioenergetic and structural support to the rapidly proliferating cells of HCC.”
BackgroundThe Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Cited by
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Self-citationObesity accelerates epigenetic aging of human liver
Horvath, S., Erhart, W., Brosch, M., Ammerpohl, O., von Schönfels, W., Ahrens, M., Heits, N., Bell, J. T., Tsai, P.-C., Spector, T. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412759111 · Cited by 766
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
“HCC may occur in the absence of cirrhosis, in particular, in patients with nonalcoholic steatohepatitis (12) or subsets of patients with HBV infection (54).”
BackgroundLiver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 755
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 736
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
The Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
“Therefore, a rapidly increasing incidence of NAFLD-HCC may be expected in the coming years.((12)) Only scant information exists about the clinical features and survival outcome of HCC on NAFLD, and a comparison with the features of HCC in viral hepatitis has not been satisfactorily addressed.”
BackgroundLiu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549
“However, if the results of the current study are corroborated, PNPLA3 rs738409 genotype could potentially be included in a broader multi-factorial risk assessment to help physicians to identify those amongst the expanding population of obese individuals with NAFLD at greatest risk of HCC, both in the presence and abse…”
BackgroundResultInfluentialHepatocellular carcinoma epidemiology
Bosetti, C., Turati, F., & La Vecchia, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.08.007 · Cited by 530
Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., & Nielsen, J. (2014) · Nature Communications · doi:10.1038/ncomms4083 · Cited by 519
Choi, J.-Y., Lee, J.-M., & Sirlin, C. B. (2014) · Radiology · doi:10.1148/radiol.14132361 · Cited by 513
Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Kanwal, F., & Singal, A. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.049 · Cited by 471
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Lally, J. S. V., Ghoshal, S., DePeralta, D. K., Moaven, O., Wei, L., Masia, R., Erstad, D. J., Fujiwara, N., Leong, V., Houde, V. P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.020 · Cited by 410
Obesity and cancer: inflammation bridges the two
Kolb, R., Sutterwala, F. S., & Zhang, W. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.005 · Cited by 405
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385
“Upon confirmation by further studies, this relationship would suggest that approaches/drugs ai ming to reduce liver fat may contribute to prevent HCC.(4-7,31) As we exploited simple yet very robust PRS based o n a limited number of validated risk variants that can be used irrespective of the prese nce of liver disease…”
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
Grohmann, M., Wiede, F., Dodd, G. T., Gurzov, E. N., Ooi, G. J., Butt, T., Rasmiena, A. A., Kaur, S., Gulati, T., Goh, P. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.053 · Cited by 373
An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 346
Self-citationFrom NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 337
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Ferslew, B. C., Xie, G., Johnston, C. K., Su, M., Stewart, P. W., Jia, W., Brouwer, K. L. R., & Sidney Barritt, A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3776-8 · Cited by 335
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Self-citationPopulation attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.5 · Cited by 320
Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review
Delli Bovi, A. P., Marciano, F., Mandato, C., Siano, M. A., Savoia, M., & Vajro, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.595371 · Cited by 289
Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection
García-Niño, W. R., & Zazueta, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.008 · Cited by 274
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., De Luca, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 263
Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease
Gentric, G., Maillet, V., Paradis, V., Couton, D., L’Hermitte, A., Panasyuk, G., Fromenty, B., Celton-Morizur, S., & Desdouets, C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73957 · Cited by 240
Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study
Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209
“It comprises a broad spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with fibrosis, which can eventually progress to cirrhosis and hepatocellular carcinoma (2, 3).”
BackgroundHepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
Dongiovanni, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12945 · Cited by 145
Bruzzì, S., Sutti, S., Giudici, G., Burlone, M. E., Ramavath, N. N., Toscani, A., Bozzola, C., Schneider, P., Morello, E., Parola, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.015 · Cited by 139
“Moreover, NAFLD/NASH is increasingly recognized as an important cause of hepatocellular carcinoma (HCC) [2].”
Pais, R., Fartoux, L., Goumard, C., Scatton, O., Wendum, D., Rosmorduc, O., & Ratziu, V. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14261 · Cited by 129
Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease
Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125
Song, B.-J., Akbar, M., Abdelmegeed, M. A., Byun, K., Lee, B., Yoon, S. K., & Hardwick, J. P. (2014) · Redox Biology · doi:10.1016/j.redox.2014.10.004 · Cited by 123
“Recent reports showed that naturally occurring antioxidants such as SAMe and betaine preserved mitochondrial function and proteome in the animal models of AFLD [212–214] as well as NAFLD [215–217], partly through blockade of the ROS/RNS production with restoring the physiological levels of SAMe, S-adenosyl-homocystein…”
BackgroundInfluentialPerumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
“The evidence of hepatocarcinogenesis arising in the absence of advanced liver disease is of particular concern since current guidelines recommend HCC screening/surveillance only in patients with cirrhosis (with the exception of patients chronically infected with HBV), missing this growing patient population entirely […”
BackgroundSeghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
Tompkins, S. C., Sheldon, R. D., Rauckhorst, A. J., Noterman, M. F., Solst, S. R., Buchanan, J. L., Mapuskar, K. A., Pewa, A. D., Gray, L. R., Oonthonpan, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.098 · Cited by 79
Ajmera, V. H., Terrault, N. A., VanWagner, L. B., Sarkar, M., Lewis, C. E., Carr, J. J., & Gunderson, E. P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.013 · Cited by 75
Insulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease
Amer, J., Salhab, A., Noureddin, M., Doron, S., Abu‐Tair, L., Ghantous, R., Mahamid, M., & Safadi, R. (2018) · Hepatology Communications · doi:10.1002/hep4.1146 · Cited by 42
Pathophysiology of hepatic Na+/H+ exchange (Review)
Li, T., & Tuo, B. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8888 · Cited by 17
An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma
DAHLQUIST, K. J. V., VOTH, L. C., FEE, A. J., & STOECKMAN, A. K. (2020) · Anticancer Research · doi:10.21873/anticanres.14628 · Cited by 13
Metadata
- Authors
- Baffy, G., Brunt, E. M., & Caldwell, S. H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 56
- Issue
- 6
- Pages
- 1384-1391
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1965712234
- Cited by
- 858
- References
- 111
- FWCI
- 51.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.